A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT03671148
- Phase
- PHASE3
- Status
- Completed
Conditions
- Psoriatic Arthritis (PsA)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — BIOLOGICALPlacebo for risankizumab administered by subcutaneous (SC) injection
- Risankizumab — BIOLOGICALRisankizumab administered by subcutaneous (SC) injection
Study Details
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Key Dates
- First listed
- Sep 14, 2018
- Start date
- Mar 7, 2019
- Status verified
- Jun 2026
- Primary completion
- Jun 22, 2020
- Completion
- Jun 4, 2026
Study Design
- Enrollment
- 444 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: RisankizumabParticipants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
- Placebo Comparator: PlaceboParticipants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
Primary Outcome Measure
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 [ Time Frame: Baseline and Week 24 ]
Locations (55)
Related coverage on Hipa.ai
- Risankizumab (Skyrizi) Phase 3 Trial Hits Primary Endpoint in Psoriatic…Risankizumab · Jun 22, 2020 · ClinicalTrials.gov
Find similar trials in Anniston, AL
Related Studies
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruiting · Brain Inflammation Collaborative · Delafield, Wisconsin
- Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled TrialPHASE4 · Not Yet Recruiting · Medical College of Wisconsin · Milwaukee, Wisconsin
- Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseasePHASE4 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas